PortalPublikationenAldosterone antagonists: silver bullet or just sodium excret...

Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention?

Standard

Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention? / Wenzel, Ulrich.

in: KIDNEY INT, Jahrgang 71, Nr. 5, 5, 2007, S. 374-376.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wenzel, U 2007, 'Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention?', KIDNEY INT, Jg. 71, Nr. 5, 5, S. 374-376. <http://www.ncbi.nlm.nih.gov/pubmed/17315004?dopt=Citation>

APA

Wenzel, U. (2007). Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention? KIDNEY INT, 71(5), 374-376. [5]. http://www.ncbi.nlm.nih.gov/pubmed/17315004?dopt=Citation

Vancouver

Wenzel U. Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention? KIDNEY INT. 2007;71(5):374-376. 5.

Bibtex

@article{215e53a8494043c2b7b8b337245f8dba,
title = "Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention?",
abstract = "ACE inhibitors or AT(1) antagonists are powerful therapeutic strategies to slow the progression of renal disease. However, they provide only imperfect protection since they cannot always prevent end-stage renal failure. Innovative approaches are needed to keep patients with chronic kidney disease off dialysis. Blockade of the aldosterone pathway may prove to be such a beneficial therapeutic concept.",
author = "Ulrich Wenzel",
year = "2007",
language = "Deutsch",
volume = "71",
pages = "374--376",
journal = "KIDNEY INT",
issn = "0085-2538",
publisher = "NATURE PUBLISHING GROUP",
number = "5",

}

RIS

TY - JOUR

T1 - Aldosterone antagonists: silver bullet or just sodium excretion and potassium retention?

AU - Wenzel, Ulrich

PY - 2007

Y1 - 2007

N2 - ACE inhibitors or AT(1) antagonists are powerful therapeutic strategies to slow the progression of renal disease. However, they provide only imperfect protection since they cannot always prevent end-stage renal failure. Innovative approaches are needed to keep patients with chronic kidney disease off dialysis. Blockade of the aldosterone pathway may prove to be such a beneficial therapeutic concept.

AB - ACE inhibitors or AT(1) antagonists are powerful therapeutic strategies to slow the progression of renal disease. However, they provide only imperfect protection since they cannot always prevent end-stage renal failure. Innovative approaches are needed to keep patients with chronic kidney disease off dialysis. Blockade of the aldosterone pathway may prove to be such a beneficial therapeutic concept.

M3 - SCORING: Zeitschriftenaufsatz

VL - 71

SP - 374

EP - 376

JO - KIDNEY INT

JF - KIDNEY INT

SN - 0085-2538

IS - 5

M1 - 5

ER -